A rating of 87 puts BioCryst Pharmaceuticals, Inc. (BCRX) near the top of the Biotechnology industry according to InvestorsObserver. BioCryst Pharmaceuticals, Inc.'s score of 87 means it scores higher than 87% of stocks in the industry. BioCryst Pharmaceuticals, Inc. also received an overall rating of 68, putting it above 68% of all stocks. Biotechnology is ranked 35 out of the 148 industries.
What do These Ratings Mean?
Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as “good” for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 68 means the stock is more attractive than 68 percent of stocks.
Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObserver’s overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. There’s no need to try to remember what is “good” for a bunch of complicated ratios, just pay attention to which numbers are the highest.
What's Happening With BioCryst Pharmaceuticals, Inc. Stock Today?
BioCryst Pharmaceuticals, Inc. (BCRX) stock is down -1.29% while the S&P 500 has risen 1.11% as of 2:09 PM on Thursday, Sep 24. BCRX has fallen -$0.05 from the previous closing price of $3.50 on volume of 4,939,567 shares. Over the past year the S&P 500 is higher by 9.65% while BCRX has risen 12.34%. BCRX lost -$0.84 per share the over the last 12 months.